Free Stock Market Quotes, Real-Time Stock Quotes, Forex Trading and Penny Stocks Banking Stock Market Earnings Penny Stocks Free Stock Trading Tips, Stock Trading Formulas and Penny Stocks.
For Day Traders and Stock Market Investors to do research and keep track of their stocks..
Level2StockQuotes.com - Free Level II Stock Quotes - Online Stock Brokers List, Penny Stocks, Stock Chart Patterns, Stock Trading Tips..
Free Level 2 Quotes | Level II Quotes | Real-Time Stock Quotes | Level 2 Charts | Live Stock Charts | Candlestick Chart Patterns | Forex Trading | Penny Stocks | Stock Research | TSX Stock Quotes
Help - Articles: FDIC - Failed Banks List | Futures Trading, Basic Introduction, Futures Contracts | How to Use Level II Quotes | Market Makers List | Stock Trading Tips | What are Level II Quotes
Level2StockQuotes.com - Penny stocks Alert, Watch: HEB Stock
Level2StockQuotes.com - Penny stock alerts for HEB penny stock. For investors looking for penny stocks that have recently reported news or has moved up in the price of the stock.
Penny stocks Picks and Alerts Archive 1: Features previous NASDAQ, NYSE, AMEX, OTC and Pink Sheets penny stocks articles and reports on companies and their stocks. Some of the stocks found here have moved up in price well over 100 or even 500 percent, that's a big increase, this movement in volume and price is what interests many online stock traders to find the next big mover in the market. For real-time penny stock picks and volume alerts, see our Penny Stock Picks and Alerts section and Find Penny Stocks in today's stock trading session. Look for stocks trading under $5 dollars and with volume / momentum coming in.
Business Summary and Article: HEB
Free Level 2 Stock Quotes Business Summary: HEB
Keep Hemispherx BioPharma, Inc. HEB on your watch-list..
Hemispherx Biopharma, Inc. (Hemispherx) is a biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's products include Ampligen and Alferon N and Injection. Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as a vaccine enhancer(adjuvant) for both therapeutic and preventative vaccine development. Alferon N is an indicator for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is an application under early stage development targeting influenza and viral diseases. Ampligen is an experimental drug undergoing clinical development for the treatment of CFS.

Article: More on HEB
HEB reported 1st qtr 2009 earnings of $-0.04 per share on 5/11/09. This beat the consensus of the analysts covering the company.

Ampligen 
The Company's double-stranded Ribonucleic Acid (RNA) drug product, Ampligen is in human clinical development for various therapeutically oriented studies, including treatment for Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS), HIV, renal cell carcinoma and malignant melanoma.

Alferon N Injection
The Company's Alferon N Injection(R) product contains a multi-species form of alpha interferon. Alpha interferons are manufactured in three ways: by genetic engineering, by cell culture, and from human white blood cells. Alferon N Injection(R) [Interferon alfa-n3] (human leukocyte derived)] is a highly purified, natural-source, glycosylated, multi-species alpha interferon product. 

Alferon(R) Low Dose Oral (LDO)
The Company's Alferon LDO is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon. It is an experimental immunotherapeutic stimulating an immune cascade response in the cells of the mouth and throat, enabling it to support systemic immune response through the entire body by absorption through the oral mucosa. The Company has conducted clinical trials of the experimental bio-therapeutic Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) for Avian Flu and other lethal viral diseases, which have high acute death rates.

Oragens
The Company acquired licenses for Oragens, a set of oral spectrum antivirals and immunological enhancers. The 2', 5' oligoadenylate synthetase/RNase L system is a distributed pathway for the inhibition of viral replication and tumor growth. The bioactive 2-5A molecules are degraded by various hydrolytic enzymes. Analogues of these bioactive 2-5As, termed Oragen RNA compounds, have been produced to increase stability and maintain or increase biological activity without demonstrable toxicity.

The Company competes with Gilead Pharmaceutical, Pfizer, Bristol-Myers, Abbott Labs, GlaxoSmithKline, Merck and Schering-Plough Corp.

Hemispherx Biopharma Press Release for Thursday, June 04, 2009
Japanese National Institute of Infectious Diseases Scientists Identify Hemispherx Biopharma's Drug Technology as the "Most Promising Mucosal Adjuvant for Influenza"

Topical Application Also Affords Strong Cross-Protection against Variant Flu Strains..
Philadelphia, PA, Thursday, June 04, 2009: Hemispherx Biopharma (NYSE AMEX: HEB) announced today that a new peer reviewed publication titled "Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses" was published in Therapeutics and Clinical Risk Management 2009:5 125-132. The article summarizes ongoing research in which researchers conclude that Poly I:PolyC12U (Ampligen), an experimental therapeutic, is the "most promising adjuvant candidate for mucosal vaccines." Poly I:PolyC12U (Ampligen), an experimental therapeutic, was also" extremely important" in these studies in that it produced cross-protection against variant influenza viruses not seen with the vaccines given alone.

For more information on Hemispherx BioPharma, Inc., visit their website at: http://www.hemispherx.net/
Note: The data and information provided here is for informational purposes only and all information on featured companies is provided by the companies profiled, or is available from other public sources. Fundamental analysis and stock market technical indicators are your responsibility, do your own research before you invest. Our recommendation is to never invest with more than you can lose. Penny stocks can pose significant risk to your capital.